Teva Respiratory Provides Resources for Patients Impacted by PRIMATENE(R) MIST Phase-Out
Published: Oct 03, 2011
HORSHAM, Pa.--(BUSINESS WIRE)--According to the United States (U.S.) Food and Drug Administration (FDA), the only over-the-counter (OTC) asthma inhaler containing chlorofluorocarbons (CFCs), Primatene® Mist, will be removed from the U.S. market on or by December 31, 2011. The removal of Primatene® Mist by the FDA is a result of the Montreal Protocol treaty to stop the use of substances that damage the environment. Primatene® Mist contains CFCs, which harm the environment by depleting the earth’s ozone layer. As a result of the removal of Primatene® Mist from the market, patients will need to see a healthcare professional to switch to another asthma medication. To help patients in this transition, Teva Respiratory is supporting patients through several programs, including financial assistance programs, asthma product samples available through healthcare professionals and asthma education resources.